Clinical Trial Update: Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing vildagliptin to glibenclamide in Type 2 diabetes assessed circulating endothelial progenitor cell counts; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glibenclamide (glibenclamide)
• Vildagliptin (vildagliptin)

Snippet

Sponsor: Azienda Ospedaliero-Universitaria di Parma | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2017-08-02